Skip to Main Content

Saracatinib (AZD0530) in the Treatment of Patients with Idiopathic Pulmonary Fibrosis

Conditions

Diseases of the Lung

Phase 1B/2

What is the purpose of this trial?

Scarring of the lung, termed pulmonary fibrosis (PF), is a chronic, progressive, and usually fatal disorder. While two anti-fibrotic drugs have recently been approved for treating PF of unknown cause (idiopathic pulmonary fibrosis or IPF), neither drug is curative, and nearly 40% of patients stop taking the prescribed drug within a year because of side effects. We propose to study the use of saracatinib, an investigational drug originally developed to treat certain types of cancers, in the treatment of IPF in a Phase 1b/2a clinical trial

Study visits every 3-4 weeks

Treatment period 28weeks

Study treatment- Saracatinib 125mg/Placebo, pill 1:1 randomization ratio

  • Trial with
    National Jewish Health
  • Start Date
    02/26/2021
  • End Date
    12/31/2023

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    07/15/2021
  • Study HIC
    #2000028835